-
2
-
-
84862874665
-
Second-line systemic therapy for the treatment of metastatic renal cell cancer
-
Kruck S, Bedke J, Kuczyk MA, et al. Second-line systemic therapy for the treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther 2012;12:777-85
-
(2012)
Expert Rev Anticancer Ther
, vol.12
, pp. 777-785
-
-
Kruck, S.1
Bedke, J.2
Kuczyk, M.A.3
-
3
-
-
21044442672
-
Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer
-
Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11:3714-21
-
(2005)
Clin Cancer Res
, vol.11
, pp. 3714-3721
-
-
Atkins, M.1
Regan, M.2
McDermott, D.3
-
4
-
-
84893663818
-
Targeted therapy in renal cell carcinoma: Moving from molecular agents to specific immunotherapy
-
published online 12 February 2013 doi: 10.1007/s00345-013-1033-3
-
Bedke J, Gouttefangeas C, Singh-Jasuja H, et al. Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. World J Urol 2013;published online 12 February 2013; doi: 10.1007/s00345-013- 1033-3
-
(2013)
World J Urol
-
-
Bedke, J.1
Gouttefangeas, C.2
Singh-Jasuja, H.3
-
5
-
-
1542327748
-
Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis
-
Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171:1071-6
-
(2004)
J Urol
, vol.171
, pp. 1071-1076
-
-
Flanigan, R.C.1
Mickisch, G.2
Sylvester, R.3
-
6
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
7
-
-
79952284127
-
Hallmarks of cancer: The next generation
-
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
-
(2011)
Cell
, vol.144
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
8
-
-
0027399243
-
Peptides naturally presented by MHC class i molecules
-
Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu Rev Immunol 1993;11:213-44
-
(1993)
Annu Rev Immunol
, vol.11
, pp. 213-244
-
-
Rammensee, H.G.1
Falk, K.2
Rotzschke, O.3
-
9
-
-
0037108856
-
Integrated functional genomics approach for the design of patient-individual antitumor vaccines
-
Weinschenk T, Gouttefangeas C, Schirle M, et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res 2002;62:5818-27
-
(2002)
Cancer Res
, vol.62
, pp. 5818-5827
-
-
Weinschenk, T.1
Gouttefangeas, C.2
Schirle, M.3
-
10
-
-
79959568681
-
Vaccination therapy in renal cell carcinoma: Current position and future options in metastatic and localized disease
-
Brookman-May S, Burger M, Wieland WF, et al. Vaccination therapy in renal cell carcinoma: current position and future options in metastatic and localized disease. Expert Rev Vaccines 2011;10:837-52
-
(2011)
Expert Rev Vaccines
, vol.10
, pp. 837-852
-
-
Brookman-May, S.1
Burger, M.2
Wieland, W.F.3
-
11
-
-
33745247366
-
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients
-
Wierecky J, Muller MR, Wirths S, et al. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006;66:5910-18
-
(2006)
Cancer Res
, vol.66
, pp. 5910-5918
-
-
Wierecky, J.1
Muller, M.R.2
Wirths, S.3
-
12
-
-
84859101225
-
Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited
-
Randazzo M, Terness P, Opelz G, et al. Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited. Int J Cancer 2012;130:2219-31
-
(2012)
Int J Cancer
, vol.130
, pp. 2219-2231
-
-
Randazzo, M.1
Terness, P.2
Opelz, G.3
-
13
-
-
78651292217
-
Allele frequency net: A database and online repository for immune gene frequencies in worldwide populations
-
Gonzalez-Galarza FF, Christmas S, Middleton D, et al. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011;39:D913-19
-
(2011)
Nucleic Acids Res
, vol.39
-
-
Gonzalez-Galarza, F.F.1
Christmas, S.2
Middleton, D.3
-
14
-
-
84864662070
-
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
-
published online 29 July 2012 doi:10.1038/nm.2883
-
Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012;published online 29 July 2012; doi:10.1038/nm.2883
-
(2012)
Nat Med
-
-
Walter, S.1
Weinschenk, T.2
Stenzl, A.3
-
15
-
-
0028326159
-
Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes
-
Celis E, Tsai V, Crimi C, et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 1994;91:2105-9
-
(1994)
Proc Natl Acad Sci USA
, vol.91
, pp. 2105-2109
-
-
Celis, E.1
Tsai, V.2
Crimi, C.3
-
16
-
-
1542267730
-
The Tubingen approach: Identification, selection, and validation of tumor-associated HLA peptides for cancer therapy
-
Singh-Jasuja H, Emmerich NP, Rammensee HG. The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol Immunother 2004;53:187-95
-
(2004)
Cancer Immunol Immunother
, vol.53
, pp. 187-195
-
-
Singh-Jasuja, H.1
Emmerich, N.P.2
Rammensee, H.G.3
-
17
-
-
80053343071
-
Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy
-
Seremet T, Brasseur F, Coulie PG. Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Cancer J 2011;17:325-30
-
(2011)
Cancer J
, vol.17
, pp. 325-330
-
-
Seremet, T.1
Brasseur, F.2
Coulie, P.G.3
-
18
-
-
0026322151
-
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
-
van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7
-
(1991)
Science
, vol.254
, pp. 1643-1647
-
-
Van Der Bruggen, P.1
Traversari, C.2
Chomez, P.3
-
19
-
-
2542526311
-
Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes
-
Schag K, Schmidt SM, Muller MR, et al. Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes. Clin Cancer Res 2004;10:3658-66
-
(2004)
Clin Cancer Res
, vol.10
, pp. 3658-3666
-
-
Schag, K.1
Schmidt, S.M.2
Muller, M.R.3
-
20
-
-
10744230512
-
Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis
-
Schmidt SM, Schag K, Muller MR, et al. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res 2004;64:1164-70
-
(2004)
Cancer Res
, vol.64
, pp. 1164-1170
-
-
Schmidt, S.M.1
Schag, K.2
Muller, M.R.3
-
21
-
-
79954458103
-
Immunological perspective of self versus tumor antigens: Insights from the RIP-gp model
-
Dissanayake D, Gronski MA, Lin A, et al. Immunological perspective of self versus tumor antigens: insights from the RIP-gp model. Immunol Rev 2011;241:164-79
-
(2011)
Immunol Rev
, vol.241
, pp. 164-179
-
-
Dissanayake, D.1
Gronski, M.A.2
Lin, A.3
-
22
-
-
14944360112
-
Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4
-
Probst HC, McCoy K, Okazaki T, et al. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat Immunol 2005;6:280-6
-
(2005)
Nat Immunol
, vol.6
, pp. 280-286
-
-
Probst, H.C.1
McCoy, K.2
Okazaki, T.3
-
23
-
-
84877940678
-
Trial watch: Peptide vaccines in cancer therapy
-
Vacchelli E, Martins I, Eggermont A, et al. Trial watch: peptide vaccines in cancer therapy. Oncoimmunology 2012;1:1557-76
-
(2012)
Oncoimmunology
, vol.1
, pp. 1557-1576
-
-
Vacchelli, E.1
Martins, I.2
Eggermont, A.3
-
25
-
-
1642578298
-
Dr William Coley and tumour regression: A place in history or in the future
-
Hoption Cann SA, van Netten JP, van Netten C. Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J 2003;79:672-80
-
(2003)
Postgrad Med J
, vol.79
, pp. 672-680
-
-
Hoption Cann, S.A.1
Van Netten, J.P.2
Van Netten, C.3
-
26
-
-
84855172987
-
Toll-like receptor 4 activation in cancer progression and therapy
-
Oblak A, Jerala R. Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol 2011;2011:609579
-
(2011)
Clin Dev Immunol
, vol.2011
, pp. 609579
-
-
Oblak, A.1
Jerala, R.2
-
27
-
-
33847258205
-
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
-
Parmiani G, Castelli C, Pilla L, et al. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007;18:226-32
-
(2007)
Ann Oncol
, vol.18
, pp. 226-232
-
-
Parmiani, G.1
Castelli, C.2
Pilla, L.3
-
28
-
-
15944410592
-
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
-
Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-8
-
(2005)
Blood
, vol.105
, pp. 2862-2868
-
-
Lutsiak, M.E.1
Semnani, R.T.2
De Pascalis, R.3
-
29
-
-
33750704266
-
Different mechanisms for anti-tumor effects of low-and high-dose cyclophosphamide
-
Motoyoshi Y, Kaminoda K, Saitoh O, et al. Different mechanisms for anti-tumor effects of low-and high-dose cyclophosphamide. Oncol Rep 2006;16:141-6
-
(2006)
Oncol Rep
, vol.16
, pp. 141-146
-
-
Motoyoshi, Y.1
Kaminoda, K.2
Saitoh, O.3
-
31
-
-
47049127786
-
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
-
Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008;111:5610-20
-
(2008)
Blood
, vol.111
, pp. 5610-5620
-
-
Hipp, M.M.1
Hilf, N.2
Walter, S.3
-
34
-
-
0033198562
-
The makings of a tumor rejection antigen
-
Gilboa E. The makings of a tumor rejection antigen. Immunity 1999;11:263-70
-
(1999)
Immunity
, vol.11
, pp. 263-270
-
-
Gilboa, E.1
-
35
-
-
0033556322
-
High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy
-
Zeh HJ III, Perry-Lalley D, Dudley ME, et al. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162:989-94
-
(1999)
J Immunol
, vol.162
, pp. 989-994
-
-
Zeh, H.J.1
Perry-Lalley, D.2
Dudley, M.E.3
-
36
-
-
84871503916
-
Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma
-
Bedke J, Laske K, Feyerabend S, et al. Clinical and immunological monitoring of a multi-peptide vaccination trial in patients with stage III renal cell carcinoma. Eur Urol Suppl 2012;11:e76-ea
-
(2012)
Eur Urol Suppl
, vol.11
-
-
Bedke, J.1
Laske, K.2
Feyerabend, S.3
-
37
-
-
34547720636
-
Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas
-
Dengjel J, Nastke MD, Gouttefangeas C, et al. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res 2006;12:4163-70
-
(2006)
Clin Cancer Res
, vol.12
, pp. 4163-4170
-
-
Dengjel, J.1
Nastke, M.D.2
Gouttefangeas, C.3
-
38
-
-
0027538181
-
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colonystimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
-
Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colonystimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43
-
(1993)
Proc Natl Acad Sci USA
, vol.90
, pp. 3539-3543
-
-
Dranoff, G.1
Jaffee, E.2
Lazenby, A.3
-
39
-
-
0034047619
-
Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colonystimulating factor or Flt3-ligand
-
Mach N, Gillessen S, Wilson SB, et al. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colonystimulating factor or Flt3-ligand. Cancer Res 2000;60:3239-46
-
(2000)
Cancer Res
, vol.60
, pp. 3239-3246
-
-
Mach, N.1
Gillessen, S.2
Wilson, S.B.3
-
40
-
-
0031570843
-
Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colonystimulating factor gene-modified tumor cells
-
Qin Z, Noffz G, Mohaupt M, et al. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colonystimulating factor gene-modified tumor cells. J Immunol 1997;159:770-6
-
(1997)
J Immunol
, vol.159
, pp. 770-776
-
-
Qin, Z.1
Noffz, G.2
Mohaupt, M.3
-
41
-
-
0029833732
-
Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancer
-
Young MR, Wright MA, Lozano Y, et al. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 1996;67:333-8
-
(1996)
Int J Cancer
, vol.67
, pp. 333-338
-
-
Young, M.R.1
Wright, M.A.2
Lozano, Y.3
-
42
-
-
0031570886
-
Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas
-
Young MR, Wright MA, Pandit R. Myeloid differentiation treatment to diminish the presence of immune-suppressive CD34+ cells within human head and neck squamous cell carcinomas. J Immunol 1997;159:990-6
-
(1997)
J Immunol
, vol.159
, pp. 990-996
-
-
Young, M.R.1
Wright, M.A.2
Pandit, R.3
-
43
-
-
4344590947
-
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells
-
Serafini P, Carbley R, Noonan KA, et al. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004;64:6337-43
-
(2004)
Cancer Res
, vol.64
, pp. 6337-6343
-
-
Serafini, P.1
Carbley, R.2
Noonan, K.A.3
-
44
-
-
0030944023
-
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
-
Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997;57:1537-46
-
(1997)
Cancer Res
, vol.57
, pp. 1537-1546
-
-
Simons, J.W.1
Jaffee, E.M.2
Weber, C.E.3
-
45
-
-
0033998594
-
Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colonystimulating factor
-
Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colonystimulating factor. J Clin Oncol 2000;18:1614-21
-
(2000)
J Clin Oncol
, vol.18
, pp. 1614-1621
-
-
Spitler, L.E.1
Grossbard, M.L.2
Ernstoff, M.S.3
-
46
-
-
67049156789
-
Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer
-
Feyerabend S, Stevanovic S, Gouttefangeas C, et al. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009;69:917-27
-
(2009)
Prostate
, vol.69
, pp. 917-927
-
-
Feyerabend, S.1
Stevanovic, S.2
Gouttefangeas, C.3
-
47
-
-
58149179532
-
Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients
-
Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82
-
(2008)
Clin Cancer Res
, vol.14
, pp. 6674-6682
-
-
Finke, J.H.1
Rini, B.2
Ireland, J.3
-
48
-
-
58149332680
-
Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma
-
Kusmartsev S, Su Z, Heiser A, et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 2008;14:8270-8
-
(2008)
Clin Cancer Res
, vol.14
, pp. 8270-8278
-
-
Kusmartsev, S.1
Su, Z.2
Heiser, A.3
-
50
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
-
(2010)
N Engl J Med
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'day, S.J.2
McDermott, D.F.3
|